1242/58 CIP

Approved for use through 05/200 MOV Uses the Group

Approved for use through 05/200 MOV Ober 0 Complete if Known Substitute for form 1449B/PTO Application Number 10/785,374 Filing Date February 24, 2004 INFORMATION DISCLOSURE First Named Inventor Summar et al. STATEMENT BY APPLICANT Art Unit 1638 **Examiner Name** D. Johannsen (Use as many sheets as necessary)

Attomey Docket Number

2

Sheet

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	miner Richard Representation of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.		T ²				
	1	Aschner, J. L., "New Theraples for Pulmonary Hypertension in Neonates and Children," Pediatr. Pulmonol. Suppl., Vol. 26, pgs. 132-135 (2004).					
	2	Blum et al., "Oral L-arginine in Patients with Coronary Artery Disease on Medical Management," Circulation, Vol. 101, pgs. 2160-2164 (May 9, 2000).					
	3	Chin-Dusting et al., "Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure," J. Am. Coll. Cardiol., Vol. 27, pgs. 1207-1213 (1996).					
	4	Feng et al., "Effects of L-arginine on endothelial and cardiac function in rats with heart failure," Eur. J. Pharmacol., Vol. 376, pgs. 37-44 (July 2, 1999).					
	5	Hladunewich et al., "Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial," Obstet. Gynecol., Vol. 107, pgs. 886-895 (2006).					
	6	Laursen et al., "Hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy is unattered by long-term oral L-arginine administration," Vascul. Pharmacol., Vol. 49, pgs. 71-76 (2008).					
Torente et al., "Modulation of systemic hemodynamics by exogenous L-arginine in non bacteremic sheep," Crit. Care Med., Vol. 27, pgs. 2474-2479 (1999).		Lorente et al., "Modulation of systemic hemodynamics by exogenous L-arginine in normal and bacteremic sheep," Crit. Care Med., Vol. 27, pgs. 2474-2479 (1999).					
	8 Miller et al., "Effects of an acute dose of L-arginine during coronary angiography in patients chronic renal failure: a randomized, parallel, double-blind clinical trial," Am. J. Nephrol., Vo pgs. 91-95 (2003)						
	9	Morris et al., "Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease," J. Pediatr. Hematol. Oncol., Vol. 25, pgs. 629-634 (2003).					
	10	Paulus et al., "Myocardial contractile effects of L-arginine in the human allograft," J. Am. Coll. Cardiol., Vol. 29, pgs. 1332-1338 (1997).					
	11	Romero et al., "Therapeutic use of citrulline in cardiovascular disease," Cardiovasc.Drug Rev., Vol. 24, pgs. 275-290 (2006).					

examiner		Date	
Signature		Considered	
*EXAMINER: I	nitial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citati	on if not in conformance and not

"EXAMINES: Intilal if reference considered, withere or not citation is in conformance with MPEP 089. Draw the through classon or not conformance airon or considered, include copy of this form with these dominational to applicant.

Applicant's unique citation designation number (optional). Applicant is to because a relect must be real English engugary Emeration: is attached. Applicant's unique citation designation number (optional). Applicant is to because a relect must be resident in the public which is the first public which is not applicant to the public which is the public which is not applicant. One of the public which is not public that the public which is not public which is not public which is not public that the public which is not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Substitute for form 1449B/PTO Complete if Known Application Number 10/785,374 Filing Date February 24, 2004 INFORMATION DISCLOSURE First Named Inventor Summar et al. STATEMENT BY APPLICANT Art Unit 1638 Examiner Name D. Johannsen (Use as many sheets as necessary) Sheet 2 Attorney Docket Number 1242/58 CIP

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, citly and/or country where published.	T ²
	12	Schulman et al., "L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial," JAMA, Vol. 295, pgs. 58-64 (January 4, 2006).	
	13	Simko et al., "L-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension," Eur. J. Clin. Invest, Vol. 35, pgs. 362-368 (2005).	
	14	Stier et al., "Dietary arginine fails to protect against cerebrovascular damage in stroke-prone hypertensive rats," Brain Res., Vol. 549, pgs. 354-356 (May 24, 1991).	
	15	Surdacki et al., "Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension," Wien. Klin. Wochenschr., Vol. 106, pgs. 521-526 (1994).	
	16	Wilson et al., "L-arginine supplementation in peripheral arterial disease: no benefit and possible harm," Circulation, Vol. 116, pgs. 188-195 (July 10, 2007).	
		·	

Examiner Signature	/Diana B. Johannsen/	Date Considered	02/20/2010			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						

EAAMINE: finals if reference considered, whether or not claised is in conformance with MPEP 69s. Draw line through claison in function conformance and not prostedered, include copy of this form with read communication to applicant. Some of the conformance of the conformance

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.